This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Spinifex Pharmaceuticals' EMA401 Named One Of The Top Ten Neuroscience Projects To Watch

MELBOURNE, Australia, October 18, 2013 /PRNewswire/ --

Company to present at Elsevier Business Intelligence's 2013 Therapeutic Area Partnerships

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces that CEO Tom McCarthy will present at Elsevier Business Intelligence's 2013 Therapeutic Area Partnerships (18-20 November in Boston, USA).

Dr McCarthy's presentation will give an overview of the Company's lead candidate, EMA401, which is a novel angiotensin II type 2 (AT 2)receptor antagonist under development as a potential first-in-class oral treatment for chronic pain without CNS side effects.

EMA401 has been selected as an Elsevier Top Ten Neuroscience Project to Watch, representing one of the most attractive investment opportunities in the industry. The rigorous judging criteria included unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities and potential for new opportunities beyond initial indications and corporate stability.      

Spinifex Pharmaceuticals has reported positive headline results from a Phase 2 clinical trial of EMA401 in post herpetic neuralgia, a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

The clinical trial met its primary endpoint, reduction in mean daily pain score versus placebo over the last week of 28 days of treatment. Results showed a statistically significant and clinically meaningful reduction in mean pain intensity from baseline to week 4 for subjects on active treatment when compared with placebo. EMA401 was generally safe and well tolerated with no serious treatment related adverse events reported. Full results of the Phase 2 trial are expected to be published in a leading clinical research journal.

Spinifex Pharmaceuticals' CEO Tom McCarthy said: "We are honoured that EMA401 has been recognised as one of the Top Ten Neuroscience Projects to Watch by Elsevier and look forward to presenting the development program at the Therapeutic Area Partnerships conference. Despite being a large and growing market, current therapy for chronic pain needs to be improved as a significant proportion of patients don't respond to current therapy and these treatments have dose limiting side effects.

"Our results so far are promising, showing a clear reduction in pain versus placebo and a good safety and tolerability profile. EMA401 offers an entirely novel approach and could eventually represent a valuable new treatment option in an area where there is a clear need for new medicines."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.21 -0.44%
FB $117.80 -0.22%
GOOG $701.26 0.80%
TSLA $211.34 -5.00%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs